Selatogrel, the reversible and specific P2Y12 receptor antagonist, does not interfere with haemostasis

被引：0
|
作者：
Riederer, M. A. [1 ]
Crescence, L. [2 ]
Caroff, E. [1 ]
Hubler, F. [1 ]
Panicot-Dubois, L. [2 ]
Dubois, C. [2 ]
机构：
[1] Idorsia Pharmaceut Ltd, Allschwil, Switzerland
[2] Aix Marseille Univ, INSEAM 1263, INRAE 1260, C2VN, Marseille, France
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3819 / 3819
页数：1
相关论文
共 50 条
  • [41] A NEW REVERSIBLE AND POTENT P2Y12 RECEPTOR ANTAGONIST: TOLERABILITY, PHARMACODYNAMICS, AND PHARMACOKINETICS IN A FIRST-IN-MAN TRIAL.
    Baldoni, D.
    Krause, A.
    Bruderer, S.
    Astruc, B.
    Dingemanse, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S34 - S34
  • [42] Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
    Hsin, Chih-hsuan
    Dingemanse, Jasper
    Henrich, Andrea
    Bernaud, Corine
    Gehin, Martine
    Krause, Andreas
    BIOMOLECULES, 2023, 13 (09)
  • [43] The future of P2Y12 receptor antagonists
    Thomas, Mark R.
    Storey, Robert F.
    PLATELETS, 2015, 26 (05) : 392 - 398
  • [44] Development of a Multi-Kilogram-Scale Synthesis of AZD1283: A Selective and Reversible Antagonist of the P2Y12 Receptor
    Andersen, Soren M.
    Aurell, Carl-Johan
    Zetterberg, Fredrik
    Bollmark, Martin
    Ehrl, Robert
    Schuisky, Peter
    Witt, Anette
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (12) : 1543 - 1551
  • [45] Pharmacokinetics and pharmacodynamics of AZD6140, the first reversible oral P2Y12 receptor antagonist, administered with aspirin.
    Butler, K.
    Winter, H.
    Mitchell, P.
    Fox, J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1204 - 1204
  • [46] A Clopidogrel-Insensitive Inducible Pool of P2Y12 Receptors Contributes to Thrombus Formation: Inhibition by Elinogrel, a Direct-Acting, Reversible P2Y12 Antagonist
    Haberstock-Debic, Helena
    Andre, Patrick
    Mills, Scott
    Phillips, David R.
    Conley, Pamela B.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2011, 339 (01): : 54 - 61
  • [47] AZD6140.: Antiplatelet therapy, P2Y12 (P2T) receptor antagonist
    Owen, R. T.
    Serradell, N.
    Bolos, J.
    DRUGS OF THE FUTURE, 2007, 32 (10) : 845 - 853
  • [48] Thrombus remodelling by reversible and irreversible P2Y12 inhibitors
    Tunstromer, Kjersti
    Faxalv, Lars
    Larsson, Pia
    Lindahl, Tomas L.
    Boknas, Niklas
    PLATELETS, 2023, 34 (01)
  • [49] Molecular mechanism of action for reversible P2Y12 antagonists
    Liu, Haibo
    Ge, Hu
    Peng, Yong
    Xiao, Peigen
    Xu, Jun
    BIOPHYSICAL CHEMISTRY, 2011, 155 (2-3) : 74 - 81
  • [50] Ticagrelor: the first novel reversible P2Y12 inhibitor
    Htun, Wah Wah
    Steinhubl, Steven R.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (02) : 237 - 245
12345